Published in Bone Marrow Transplant on May 31, 2010
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation | NCT01916577
Current clinical indications for plerixafor. Transfus Med Hemother (2013) 0.86
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. Bone Marrow Transplant (2012) 0.85
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher (2012) 0.84
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2014) 0.82
New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis (2012) 0.81
Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. J Oncol (2012) 0.80
The nucleotide sugar UDP-glucose mobilizes long-term repopulating primitive hematopoietic cells. J Clin Invest (2013) 0.79
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Blood Cancer J (2014) 0.79
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Blood Transfus (2012) 0.79
An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. Bone Marrow Transplant (2014) 0.78
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis. PLoS One (2016) 0.77
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant (2016) 0.77
Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma. Stem Cells Cloning (2011) 0.76
Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients. Adv Hematol (2011) 0.75
Plerixafor in the treatment of stem cell mobilization failure; first experience in iran. Iran J Pharm Res (2013) 0.75
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transplant (2013) 0.75
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia (2006) 5.64
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst (1998) 2.96
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. Clin Endocrinol (Oxf) (2001) 1.89
CPAP and measures of cardiovascular risk in males with OSAS. Eur Respir J (2008) 1.85
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol (2009) 1.62
The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. J Clin Endocrinol Metab (2000) 1.61
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood (1996) 1.59
Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res (2003) 1.55
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology (Oxford) (2003) 1.51
Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression. Cardiovasc Res (2005) 1.48
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol (2000) 1.46
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas. Br J Haematol (1997) 1.45
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med (1997) 1.44
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
A template-based approach to support utilization of clinical practice guidelines within an electronic health record. J Am Med Inform Assoc (1998) 1.44
Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion (1998) 1.43
Angiotensin-converting enzyme inhibition and physical training in heart failure. J Intern Med (1991) 1.42
Invasive sinusitis with intracranial extension caused by Curvularia lunata. Arch Intern Med (1993) 1.42
Microbiologic contamination of intraoperative blood salvaged during liver transplantation. Transplant Proc (2007) 1.41
Effects of athletic training on neural control of heart rate. Cardiovasc Res (1993) 1.40
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
In situ staining of bromodeoxyuridine positive cells in normal and neoplastic colony-forming units grown on plasma clots. J Immunol Methods (1988) 1.38
Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol (1985) 1.30
A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.27
Should we still use nitrovasodilators to test baroreflex sensitivity? J Hypertens (2000) 1.26
Metal-related artifacts in instrumented spine. Techniques for reducing artifacts in CT and MRI: state of the art. Eur Spine J (2009) 1.26
Identification of higher brain centres that may encode the cardiorespiratory response to exercise in humans. J Physiol (2001) 1.21
The role of infections with Yersinia pseudotuberculosis and Yersinia enterocolitica in the pathogenesis of chronic inflammatory, rheumatic and collagen diseases. Med Interne (1986) 1.20
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol (2009) 1.20
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol (2000) 1.18
Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant (2012) 1.17
Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program (2001) 1.16
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica (2001) 1.16
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol (2006) 1.16
Staging and prognosis in chronic myelogenous leukemia. Semin Hematol (1988) 1.15
Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia (2011) 1.15
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia (2006) 1.15
Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). Circ Res (1997) 1.14
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol (2008) 1.14
Accelerated bone mass senescence after hematopoietic stem cell transplantation. Transl Med UniSa (2013) 1.13
The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood (1994) 1.12
A mathematical model of the murine ventricular myocyte: a data-driven biophysically based approach applied to mice overexpressing the canine NCX isoform. Am J Physiol Heart Circ Physiol (2010) 1.12
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer (2012) 1.11
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia (2013) 1.11
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer (2004) 1.10
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood (2000) 1.10
Tunable band gap in hydrogenated quasi-free-standing graphene. Nano Lett (2010) 1.10
Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology (2000) 1.10
Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest (2008) 1.08
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica (1999) 1.07
Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol (1995) 1.05
Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev (1999) 1.05
An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med (2006) 1.04
Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol (1999) 1.03
Direct observation of defect structure in protein crystals by atomic force and transmission electron microscopy. Biophys J (1992) 1.03
Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia (2005) 1.03
Determinants of spontaneous baroreflex sensitivity in a healthy working population. Hypertension (2001) 1.03
The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. Haematologica (1992) 1.02
Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell precursors. J Immunol (2001) 1.01
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia (2002) 1.01
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia (2013) 1.01
Ventilation in chronic heart failure: effects of physical training. Br Heart J (1992) 1.00
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia (2011) 1.00
OPSI threat in hematological patients. Transl Med UniSa (2013) 0.99
Serum LDH concentration in non-Hodgkin's lymphomas. Relationship to histologic type, tumor mass, and presentation features. Acta Haematol (1984) 0.98
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia (2012) 0.98
Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant (2005) 0.98
Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Blood (1982) 0.98
Cell therapy: achievements and perspectives. Haematologica (1999) 0.98
Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood (2001) 0.97
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant (2011) 0.97
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. Leukemia (2009) 0.96
Nitric oxide donors can increase heart rate independent of autonomic activation. J Appl Physiol (1985) (1999) 0.96
Bronchoalveolar lavage in bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast. J Allergy Clin Immunol (2000) 0.96
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia (2011) 0.96
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol (2000) 0.95
Evaluating the impact of structured text and templates in ambulatory nursing. Proc Annu Symp Comput Appl Med Care (1995) 0.95
Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer (1999) 0.95
Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood (2001) 0.95
Stem cell mobilization and collection in patients with liver cirrhosis. Aliment Pharmacol Ther (2008) 0.95
Splenectomy in hematology. Current practice and new perspectives. Haematologica (1999) 0.94
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia (2010) 0.94
Hodgkin's disease occurring in a Warthin's tumor: first case report. Pathol Res Pract (1986) 0.94
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest (2007) 0.94
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J (2012) 0.94